B-cell Acute Lymphoblastic Leukemia

NCI Standard risk B-cell Acute Lymphoblastic Leukemia – Ten year outcome from India. Where are we heading towards?
CD19 Chimeric Antigen Receptor (CAR) T- Cell therapy with Tisagenlecleucel in Children with B-Cell Acute Lymphoblastic Leukemia: Preliminary Findings from a Tertiary Care Center
Prognostic Significance of CD79a Expression in Paediatric B-Cell Acute Lymphoblastic Leukaemia: Implications for Risk Stratification and Therapeutic Targeting